Chatterjee R, Narayan KM, Lipscomb J, et al
The accelerated approval is supported by results from the Phase III ESSENCE trial, which showed that nearly two thirds of participants who received weekly injections of Wegovy experienced MASH resolution without worsening fibrosis, while more than a third showed fibrosis improvement without worsening MASH
Conclusion: A More Reassuring Picture, With a Call for Vigilance This comprehensive analysis provides strong evidence that for the majority of patients with obesity but without major pre-existing psychiatric conditions, tirzepatide does not appear to increase the risk of depression or suicidal thoughts
Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model
Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases
IV Infusion Therapy: Hydration and Vitality at Your Fingertips Summer adventures often lead to dehydration and nutrient depletion